What is International Stem Cell Return-on-Tangible-Asset?
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. International Stem Cell's annualizedNet Income for the quarter that ended in Mar. 2024 was $-0.86 Mil. International Stem Cell's average total tangible assets for the quarter that ended in Mar. 2024 was $4.59 Mil. Therefore, International Stem Cell's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -18.65%.
The historical rank and industry rank for International Stem Cell's Return-on-Tangible-Asset or its related term are showing as below:
ISCO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -252.77 Med: -52.77 Max: -2.96
Current: -6.64
During the past 13 years, International Stem Cell's highest Return-on-Tangible-Asset was -2.96%. The lowest was -252.77%. And the median was -52.77%.
ISCO's Return-on-Tangible-Asset is ranked better than 77.48% of 1550
companies
in the Biotechnology industry
Industry Median: -40.42
vs ISCO: -6.64
International Stem Cell Return-on-Tangible-Asset Historical Data
The historical data trend for International Stem Cell's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
International Stem Cell Return-on-Tangible-Asset Chart
Competitive Comparison of International Stem Cell's Return-on-Tangible-Asset
For the Biotechnology subindustry, International Stem Cell's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell's Return-on-Tangible-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Return-on-Tangible-Asset falls into.
International Stem Cell Return-on-Tangible-Asset Calculation
International Stem Cell's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2024) net income data.
International Stem Cell (OTCPK:ISCO) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
International Stem Cell Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of International Stem Cell's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
International Stem Cell (International Stem Cell) Business Description
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ISCO has been successfully added to your 